View : 732 Download: 0

Full metadata record

DC Field Value Language
dc.contributor.author이순남-
dc.date.accessioned2016-08-27T02:08:02Z-
dc.date.available2016-08-27T02:08:02Z-
dc.date.issued2009-
dc.identifier.issn1598-2998-
dc.identifier.otherOAK-1969-
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/215734-
dc.description.abstractPurpose Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer. Materials and Methods One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400 mg/m(2)) or cisplatin (60 mg/m(2)) was given over 1 hour with 5-FU (1 gm/m(2)) on days 1 similar to 5 every 4 weeks. Results At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3 similar to 4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatment-related deaths. Conclusion Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.-
dc.languageEnglish-
dc.publisherKOREAN CANCER ASSOCIATION-
dc.subjectCombination chemotherapy-
dc.subjectAdvanced gastric cancer-
dc.subjectHeptaplatin-
dc.titleRandomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer-
dc.typeArticle-
dc.relation.issue1-
dc.relation.volume41-
dc.relation.indexSCIE-
dc.relation.indexSCOPUS-
dc.relation.indexKCI-
dc.relation.startpage12-
dc.relation.lastpage18-
dc.relation.journaltitleCANCER RESEARCH AND TREATMENT-
dc.identifier.doi10.4143/crt.2009.41.1.12-
dc.identifier.wosidWOS:000208486400002-
dc.author.googleLee, Kyung Hee-
dc.author.googleHyun, Myung Soo-
dc.author.googleKim, Hoon-Kyo-
dc.author.googleJin, Hyung Min-
dc.author.googleYang, Jinmo-
dc.author.googleSong, Hong Suk-
dc.author.googleDo, Young Rok-
dc.author.googleRyoo, Hun Mo-
dc.author.googleChung, Joo Seop-
dc.author.googleZang, Dae Young-
dc.author.googleLim, Ho-Yeong-
dc.author.googleJin, Jong Youl-
dc.author.googleYim, Chang Yeol-
dc.author.googlePark, Hee Sook-
dc.author.googleKim, Jun Suk-
dc.author.googleSohn, Chang Hak-
dc.author.googleLee, Soon Nam-
dc.contributor.scopusid이순남(8422735900;56949372000)-
dc.date.modifydate20220112143047-
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE